Dendritic cells: the yin and yang in disease progression

• Published in: Frontiers in immunology Vol. 14; p. 1321051
• Main Authors: Jiménez-Cortegana, Carlos, Palomares, Francisca, Alba, Gonzalo, Santa-María, Consuelo, de la Cruz-Merino, Luis, Sánchez-Margalet, Victor, López-Enríquez, Soledad
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 04.01.2024
• Subjects: cancer; dendritic cell; immunity; Immunology; inflammation; inflammatory bowel disease; cancer; immunity; inflammation; dendritic cell; inflammatory bowel disease
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2023.1321051

Dendritic cells (DCs) are antigen presenting cells that link innate and adaptive immunity. DCs have been historically considered as the most effective and potent cell population to capture, process and present antigens to activate naïve T cells and originate favorable immune responses in many diseases, such as cancer. However, in the last decades, it has been observed that DCs not only promote beneficial responses, but also drive the initiation and progression of some pathologies, including inflammatory bowel disease (IBD). In line with those notions, different therapeutic approaches have been tested to enhance or impair the concentration and role of the different DC subsets. The blockade of inhibitory pathways to promote DCs or DC-based vaccines have been successfully assessed in cancer, whereas the targeting of DCs to inhibit their functionality has proved to be favorable in IBD. In this review, we (a) described the general role of DCs, (b) explained the DC subsets and their role in immunogenicity, (c) analyzed the role of DCs in cancer and therapeutic approaches to promote immunogenic DCs and (d) analyzed the role of DCs in IBD and therapeutic approaches to reduced DC-induced inflammation. Therefore, we aimed to highlight the “yin-yang” role of DCs to improve the understand of this type of cells in disease progression.